CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation

On April 3, 2023 Chimeric Therapeutics Ltd (ASX:CHM)’s reported that CHM 1101 glioblastoma abstract has been selected for presentation at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), which is being held from 2-6 June 2023 in Chicago, Illinois (Press release, Chimeric Therapeutics, APR 3, 2023, View Source [SID1234629739]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract titled ‘Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma’ was selected for presentation from more than 6,500 abstracts submitted.

Chimeric noted that it is pleased that ASCO (Free ASCO Whitepaper) has selected the abstract for presentation as it highlights the clinical trial design and objectives of the company’s new multi-site Phase 1B clinical trial with CHM 1101 in patients with recurrent or progressive glioblastoma (GBM).

Details of the abstract presentation are as follows:

Section: Central Nervous System Tumors

Abstract #: 418236

Title: Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma

Session Date and Time: 3 June 2023, 1:15 PM-4:15 PM

Phase 1 clinical trial
Last month, Chimeric welcomed the initiation of the fourth dose cohort of City of Hope’s phase 1 clinical trial evaluating the safety and tolerability of Chimeric’s CHM 1101 cell therapy.

The first patient in the fourth dose cohort in the phase 1 clinical trial in recurrent/progressive glioblastoma has received dosing at City of Hope Cancer Center in the US.

This cohort will see patients treated at a total dose of 440 X 106 CHM 1101 (CLTX CAR T cells) through dual routes of intratumoral and intraventricular administration.

Progression to this level follows the successful completion of the third dose cohort without any dose-limiting toxicities in January 2023.